Objetivo Age-related degeneration of the cervical spine affects over 50% of middle-aged people causing pressure on the nerves leading to pain and neurological deficits. Where conservative treatment is not effective, an “anterior cervical discectomy with fusion” (ACDF) is performed. The source of the compression; a herniated disc or bony spurs are removed to relieve the pressure. A cervical implant and bone graft are placed in the intervertebral disc space to fuse the 2 vertebrae together (arthrodesis) in order to stabilise the neck. Currently, a bone graft, usually taken from the patient’s pelvis, is used as a substrate for cervical arthrodesis. However, 15 out of 16 complications for spinal surgery are reported to arise from the donor site including pain and infection. Currently, all cervical implants require a bone graft unless they are “custom made” using Electron Beam Melting (EBM) and hence very expensive. The cost of the EBM manufactured implant is prohibitive for government health service providers and is only available to private patients. EBM is also reported to have manufacturing defects, including porous (unmelted or unsintered) zones, inclusions and gas bubbles trapped in the atomised powder particles and retained in the manufactured product. We have developed a Titanium cervical fusion cage, Lattice Cage, using 3D additive manufacturing to form an osteoconductive structure to eliminate the use of bone grafts and to aid fusion by promoting cell (osteoblast) proliferation, driving the new bone growth. Our off the shelf implants manufactured using 3D laser sintering will be ~ 50% cheaper than any other Ti implants manufactured using EBM, will reduce surgical costs and decrease post-operative complicationsTo support commercialisation of Lattice Cage, Winsor Medical is applying for dedicated SMEI funding, initially for Phase 1, to map out the route to regulatory approval, clinical investigations and full commercialisation. Ámbito científico medical and health sciencesclinical medicinerheumatologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesclinical medicinesurgerysurgical proceduresengineering and technologymechanical engineeringmanufacturing engineeringadditive manufacturingmedical and health sciencesmedical biotechnologyimplantsartificial bone Programa(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Tema(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Convocatoria de propuestas H2020-SMEInst-2016-2017 Consulte otros proyectos de esta convocatoria Convocatoria de subcontratación H2020-SMEINST-1-2016-2017 Régimen de financiación SME-1 - SME instrument phase 1 Coordinador WINSOR MEDICAL LIMITED Aportación neta de la UEn € 50 000,00 Dirección UNIT 4 HIGHLAND BUSINESS PARK LONDON ROAD BOLNEY RH17 5PX WEST SUSSEX Reino Unido Ver en el mapa Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí Región South East (England) Surrey, East and West Sussex West Sussex (North East) Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 71 429,00
